Cardiost is a pioneering venture co-founded with the overarching goal of enhancing both the length and quality of life (QoL) for patients grappling with Heart Failure. This initiative stems from the recognition that existing FDA-approved device-based therapies and pharmacological treatments have fallen short in addressing the pressing needs of this patient demographic, failing to adequately reduce mortality rates and curb readmissions.At the forefront of our endeavors is the development of the Left Atrium Unloading Device (LAUD), a fully implantable, long-term mechanical circulatory support (MCS) device. What sets LAUD apart is its remarkable level of invasiveness in comparison to existing competitors. Specifically designed to target two pivotal metrics that have demonstrated a positive impact on Heart Failure patients with preserved ejection fraction (HFpEF), LAUD aims to enhance cardiac output while concurrently reducing left atrial pressure.Our mission is to extend the reach of this groundbreaking solution to hundreds of thousands of patients worldwide who currently endure a significantly diminished QoL, recurrent hospitalizations, and a lack of viable treatment options.In our pursuit of excellence, Cardiost has collaborated with esteemed institutions such as the University of Denver's Cardiovascular Biomechanics Lab for pump design, the University of Colorado Boulder for a proprietary induction charging mechanism, and Universidad de los Andes for Computational Fluid Dynamics (CFD) simulations. Notably, we have recently secured a grant from the state of Colorado and welcomed our inaugural investor. As we gear up to submit our NIH Phase I Grant application in early January 2024, we are actively seeking collaborations that can propel us closer to our overarching goal.Should you have an interest in learning more about our transformative work, please do not hesitate to reach out to us at info@cardiost.com
Listed skills include Strategy, Business Development, Financial Analysis, Business Strategy, and 29 others.